HC Wainwright & Co. Reiterates Buy on Century Therapeutics, Maintains $13 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Century Therapeutics (NASDAQ:IPSC), maintaining a $13 price target.
March 15, 2024 | 10:38 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Century Therapeutics maintains a Buy rating and a $13 price target from HC Wainwright & Co.
The reiteration of a Buy rating and maintenance of a $13 price target by a reputable analyst firm like HC Wainwright & Co. could instill confidence in investors, potentially leading to a positive short-term impact on Century Therapeutics' stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100